OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
4
Results
Show all
Save search
Copy query
Show results for
Unknown
(4)
Publication Date
Release Date
2024
(1)
2020
(1)
2014
(1)
2012
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).
Not available
S-EPMC4105484
|
biostudies-literature
Cite
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
Not available
S-EPMC3494835
|
biostudies-literature
Cite
Extracorporeal Life Support Organization Registry International Report 2022: 100,000 Survivors.
Not available
S-EPMC10962646
|
biostudies-literature
Cite
Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans.
Not available
S-EPMC7272903
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets